Method, apparatus, medium, program for determining attribute information regarding tumor nucleic acid sequences, and method for signal enrichment

HK40137256APending Publication Date: 2026-09-11GUANGZHOU BURNING ROCK DX CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
HK42026125034
Authority / Receiving Office
HK · HK
Patent Type
Applications
Current Assignee / Owner
Filing Date
2026-06-18
Publication Date
2026-09-11

Smart Images

  • Figure 00000000_0000_ABST
    Figure 00000000_0000_ABST
Patent Text Reader

Abstract

The present invention relates to a method, a device, a medium, a program product and a method for enriching a signal for determining attribute information about a tumor nucleic acid sequence. The method comprises the following steps: selecting 3-7 adjacent CpG series regions on a target genome to obtain a plurality of candidate DNA methylation markers so as to determine a target DNA methylation marker combination; removing sample specific biological noise in the target DNA methylation marker combination to obtain the filtered target DNA methylation marker combination for tumor abundance calculation of the sample to be detected; based on methylation sequencing result data of the to-be-detected sample, the total sequencing molecule number and the signal molecule number of each signal marker are obtained and input into a pre-trained evaluation model, the tumor abundance and the statistical test p value are calculated, and the attribute information of the to-be-detected sample about the tumor nucleic acid sequence is determined, the attribute information comprises tumor nucleic acid existence characteristic information and abundance information. The method has the advantages of high detection sensitivity and convenient detection process.
Need to check novelty before this filing date? Find Prior Art

Description

Abstract The present invention relates to apparatus, medium, program product for determining attribute information regarding tumor nucleic acid sequences, and method for signal enrichment. The method comprises: selecting 3-7 adjacent CpG tandem regions on a target genome to obtain a plurality of candidate DNA methylation markers so as to determine a target DNA methylation marker combination; removing sample specific biological noise in the target DNA methylation marker combination to obtain a filtered target DNA methylation marker combination for tumor abundance calculation of the test sample; obtaining the total sequencing molecule number and the signal molecule number of each signal marker based on methylation sequencing result data of the test sample, inputting into a pre-trained evaluation model, calculating the tumor abundance and a statistical test p value, thereby determining the attribute information of the text sample about the tumor nucleic acid sequence, the attribute information comprises tumor nucleic acid existence characteristic information and abundance information. The present invention offers both high detection sensitivity and a convenient detection process.

Claims

1. A method for determining attribute information about tumor nucleic acid sequences, characterized in that, include: Select 3-7 adjacent tandem regions of cytosine phosphate guanine on the target genome to obtain multiple candidate DNA methylation markers, so as to screen multiple candidate DNA methylation markers based on the methylation sequencing results of the predetermined sample to determine the combination of target DNA methylation markers; The determined sample-specific biological noise is removed from the target DNA methylation marker combination to obtain a filtered target DNA methylation marker combination as a signal marker combination for the test sample, used for tumor abundance calculation of the test sample; Based on the methylation sequencing results of the sample to be tested, obtain the total number of sequencing molecules and the number of signal molecules for each signal marker; By inputting the total number of sequenced molecules and the number of signal molecules of each signal marker of the sample to be tested into a pre-trained evaluation model, the tumor abundance and statistical test p-value are calculated in order to determine the attribute information of the sample to be tested regarding the tumor nucleic acid sequence. The attribute information includes at least the tumor nucleic acid presence characteristic information and the tumor nucleic acid abundance information.

2. The method according to claim 1, characterized in that, Based on the methylation sequencing results of a predetermined sample, multiple candidate DNA methylation biomarkers are screened to determine the target DNA methylation biomarker combination, including: The methylation sequencing results of the predetermined samples are used to traverse the whole genome of candidate DNA methylation markers, thereby obtaining multiple feature values ​​for each candidate DNA methylation marker. The predetermined samples include: tumor tissue samples, tumor plasma samples, and plasma samples of healthy subjects or negative plasma samples related to tumor nucleic acid sequences. The acquired feature values ​​are compared with corresponding preset thresholds to screen for detectable markers from candidate DNA methylation markers; and The selected biomarkers with detection capabilities are combined into a gene detection biomarker combination to serve as target DNA methylation biomarkers.

3. The method according to claim 2, characterized in that, The multiple characteristic values ​​include: the noise level of plasma samples from healthy subjects or negative plasma samples related to tumor nucleic acid sequences, the signal level of plasma samples from tumor subjects, the ratio of the signal level of plasma samples from tumor subjects to the noise level of plasma samples from healthy subjects or negative plasma samples related to tumor nucleic acid sequences, and the signal occurrence rate of tissue samples from tumor subjects.

4. The method according to claim 1, characterized in that, Obtaining a filtered combination of target DNA methylation biomarkers as a signal biomarker combination for the test sample, used for tumor abundance calculation of the test sample, includes: For DNA fragments that exhibit methylation signals on the filtered target DNA methylation marker combination, the probability that the DNA fragments with methylation signals originate from tumor cells and normal cells is calculated in order to determine whether to include the DNA fragments with methylation signals in the count of signal molecules.

5. The method according to claim 4, characterized in that, Determining whether to include DNA fragments containing methylation signals in the count of signaling molecules includes: For DNA fragments that exhibit methylation signals on the filtered target DNA methylation marker combination, the probability that the DNA fragments with methylation signals originate from tumor cells and the probability that they originate from normal cells are calculated. Determine whether the probability of the current DNA fragment containing methylation signals originating from tumor cells is greater than or equal to the probability of originating from normal cells; In response to the probability that the current DNA fragment containing methylation signals originates from tumor cells is greater than or equal to the probability of originating from normal cells, the current DNA fragment is identified as a positive fragment so that it is included in the count of signal molecules; and In response to the fact that the probability of a current DNA fragment containing a methylation signal originating from a tumor cell is less than the probability of it originating from a normal cell, the current DNA fragment is determined to be a negative fragment so that it is not included in the count of signal molecules.

6. The method according to claim 5, characterized in that, Calculating the probability that a DNA fragment containing methylation signals originates from tumor cells and normal cells includes: The methylation state transition matrix of adjacent cytosine phosphate guanine is calculated based on a predetermined sample. The state transition matrix includes a tumor cell metastasis matrix and a normal cell metastasis matrix. The predetermined sample includes: plasma samples from tumor subjects, and plasma samples from healthy subjects or negative plasma samples related to tumor nucleic acid sequences. Calculate the joint probability of the methylation status of adjacent cytosine phosphate guanine in a DNA fragment containing a methylation signal within a tumor cell metastasis matrix, so as to calculate the probability that the DNA fragment containing the methylation signal originates from a tumor cell based on the joint probability; and Calculate the joint probability of the methylation state of adjacent cytosine guanine phosphate in a DNA fragment containing a methylation signal in a normal cell transfer matrix, so as to calculate the probability that the DNA fragment containing the methylation signal originates from a normal cell based on the joint probability.

7. The method according to claim 1, characterized in that, The sample-specific biological noise was determined by the following: Tumor abundance was calculated using all target DNA methylation markers; Based on the calculated tumor abundance, the model noise of the current target DNA methylation marker, and the signal of the target DNA methylation marker, the theoretical abundance of the current target DNA methylation marker is calculated. Calculate the observed abundance of the current target DNA methylation marker, wherein the observed abundance conforms to a beta distribution; Calculate the observed abundance of the current target DNA methylation marker corresponding to the cumulative predetermined probability of the beta distribution, so as to compare the observed abundance with the product of the theoretical abundance and the predetermined fold. as well as In response to determining that the corresponding observed abundance is greater than the product, the current target DNA methylation marker is determined to be sample-specific biological noise.

8. The method according to claim 1, characterized in that, The sample-specific biological noise was determined by the following: In response to the determination that methylation sequencing data for a leukocyte sample of the test sample is available, for each target DNA methylation marker in the target DNA methylation marker combination, the number of signal molecules on the current target DNA methylation marker for the leukocyte sample of the test sample is determined, wherein the leukocyte sample is extracted after centrifugation of the test sample; Determine whether the number of signal molecules is greater than "0"; and In response to determining that the number of signal molecules is greater than "0", the current target DNA methylation marker is determined to be sample-specific biological noise.

9. The method according to claim 1, characterized in that, The pre-trained evaluation model is a corrected evaluation model, and the method further includes: In response to the methylation sequencing data of signal molecules in a baseline blood sample that is associated with the test sample, the tumor abundance of the baseline blood sample is calculated so as to correct for the model prior signal abundance of the filtered target methylation biomarker using the calculated tumor abundance of the baseline blood sample.

10. The method according to claim 9, characterized in that, In response to methylation sequencing data of signal molecules from a baseline blood sample that indicates an association with the test sample, the tumor abundance of the baseline blood sample is calculated. This is used to correct for the model prior signal abundance of the filtered target methylation biomarker using the calculated tumor abundance of the baseline blood sample, including: In response to methylation sequencing data of signal molecules from baseline blood samples that indicate an association with the test sample, tumor abundance in the baseline blood samples is calculated; and The tumor abundance of the calculated baseline blood sample was used to correct for the model prior signal abundance of the target methylation biomarker.

11. The method according to claim 1, characterized in that, Determining the attribute information of the test sample regarding the tumor nucleic acid sequence includes: determining the presence and abundance information of circulating tumor DNA in the test sample regarding the tumor nucleic acid sequence.

12. The method according to claim 1, characterized in that, Determining the attribute information of the sample to be tested regarding the tumor nucleic acid sequence includes: Compare the calculated statistical test p-value of the sample to be tested with the significance level threshold; In response to determining that the calculated statistical test p-value of the test sample is greater than or equal to the significance level threshold, the test result of the test sample is determined to conform to the first feature pattern; and In response to the determination that the statistical test p-value of the calculated sample is less than the significance level threshold, it is determined that the test result of the sample conforms to the second feature pattern.

13. A computing device, characterized in that, include: At least one processing unit; At least one memory coupled to the at least one processing unit and storing instructions for execution by the at least one processing unit, the instructions, when executed by the at least one processing unit, causing the device to perform the steps of the method according to any one of claims 1 to 12.

14. A computer-readable storage medium, characterized in that, A computer-readable storage medium stores a computer program that, when executed by a machine, implements the method according to any one of claims 1 to 12.

15. A computer program product, characterized in that, The computer program product includes instructions that, when executed by a machine, implement the method according to any one of claims 1 to 12.

16. A method for enriching a signal, wherein the enriched signal is used in the method according to any one of claims 1 to 12, characterized in that, The method includes: A one-sided probe design was used for the regions of the selected target DNA methylation marker combinations. A single-sided probe design was used for the other screened stable hypomethylated regions; and A two-sided probe design was used for the additional genomic quality control regions that were screened.

17. The method according to claim 16, characterized in that, Also includes: Whole-genome hypermethylation was performed on the reference sample to obtain a hypermethylated sample. The highly methylated sample was mixed with the negative reference sample at a predetermined mass ratio to obtain a mixed sample; Sequencing was performed on hypermethylated and mixed samples in order to obtain a corrected baseline based on the sequencing results; as well as Using the obtained calibration baseline, the number of non-signal molecules captured by the bilateral probe is inferred for calibration against the tumor abundance of the test sample.